Solventum Q4 sales beat estimates on $2B revenue despite 3.7% drop
Solventum reported Q4 CY2025 revenue of $2.00B, down 3.7% year-on-year but 1.9% above analysts’ $1.96B forecast, while GAAP EPS of $0.36 missed consensus by 37.3%. Organic revenue rose 3.5% and operating margin held at 6.2%, with market cap at $13.02B.
1. Q4 CY2025 Financial Results
Solventum delivered $2.00 billion in Q4 CY2025 revenue, representing a 3.7% year-on-year decline but surpassing the $1.96 billion consensus by 1.9%. The company’s organic revenue rose 3.5%, reflecting underlying demand for key healthcare solutions.
2. Earnings and Margins
The company reported GAAP EPS of $0.36, falling 37.3% short of the $0.57 estimate. Operating margin remained steady at 6.2% year-on-year, while free cash flow margin contracted to 1.7% from 4.4%.
3. Market Capitalization and Outlook
Following the release, Solventum’s market capitalization stands at $13.02 billion. Analysts forecast a 3.3% revenue decline over the next 12 months, suggesting potential headwinds for medical device and healthcare product demand.